Literature DB >> 15261807

Quantification of Doxorubicin and metabolites in rat plasma and small volume tissue samples by liquid chromatography/electrospray tandem mass spectroscopy.

Robert D Arnold1, Jeanine E Slack, Robert M Straubinger.   

Abstract

The anthracycline Doxorubicin (DXR) is used widely for the treatment of human malignancies, and drug delivery technologies are under investigation to enhance antitumor selectivity and effectiveness. A liquid chromatography-tandem mass spectroscopy (LC-MS/MS) method was developed to identify and quantify DXR and key metabolites in small-volume biological samples. The assay was linear over the therapeutically relevant concentration range (0.125-10,000 nM); in brain tissue, the lower limit of quantification was 0.247 nM and the sensitivity was 1.4 pg. The ability to quantify DXR and detect metabolite formation may provide insight into the toxicity and bioavailability of drug incorporated into carriers such as liposomes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15261807      PMCID: PMC2896316          DOI: 10.1016/j.jchromb.2004.04.030

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  33 in total

1.  Adriamycin metabolism in man. Evidence from urinary metabolites.

Authors:  S Takanashi; N R Bachur
Journal:  Drug Metab Dispos       Date:  1976 Jan-Feb       Impact factor: 3.922

2.  High-performance liquid chromatographic determination of doxorubicin and its metabolites in plasma and tissue.

Authors:  L M Rose; K F Tillery; S M el Dareer; D L Hill
Journal:  J Chromatogr       Date:  1988-03-18

3.  Adriamycin (NSC-123,127): a new antibiotic with antitumor activity.

Authors:  A Di Marco; M Gaetani; B Scarpinato
Journal:  Cancer Chemother Rep       Date:  1969-02

4.  Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes.

Authors:  M A Le Bot; J M Bégué; D Kernaleguen; J Robert; D Ratanasavanh; J Airiau; C Riché; A Guillouzo
Journal:  Biochem Pharmacol       Date:  1988-10-15       Impact factor: 5.858

Review 5.  Anthracyclines: recent developments in their separation and quantitation.

Authors:  G Zagotto; B Gatto; S Moro; C Sissi; M Palumbo
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2001-11-25

Review 6.  [Pharmacokinetics of new anthracyclines].

Authors:  J Robert
Journal:  Bull Cancer       Date:  1988       Impact factor: 1.276

7.  Determination of the concentration of adriamycin and its metabolites in the serum and tissues of Ehrlich carcinoma-bearing mice by high-performance liquid chromatography.

Authors:  S Shinozawa; Y Mimaki; Y Araki; T Oda
Journal:  J Chromatogr       Date:  1980-08-29

8.  Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times.

Authors:  A Gabizon; R Shiota; D Papahadjopoulos
Journal:  J Natl Cancer Inst       Date:  1989-10-04       Impact factor: 13.506

9.  Hepatic metabolism of doxorubicin in mice and rats.

Authors:  P Vrignaud; D Londos-Gagliardi; J Robert
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Apr-Jun       Impact factor: 2.441

Review 10.  Liposomal encapsulated anthracyclines: new therapeutic horizons.

Authors:  F M Muggia
Journal:  Curr Oncol Rep       Date:  2001-03       Impact factor: 5.945

View more
  24 in total

1.  A HPLC method for the quantitative determination of N-(2-hydroxy-5-nitrophenylcarbamothioyl)-3,5-dimethylbenzamide in biological samples.

Authors:  Igor Skidan; Jacob Grunwald; Ritesh Thekkedath; Alexei Degterev; Vladimir Torchilin
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-04-06       Impact factor: 3.205

2.  Pharmacokinetics, antitumor and cardioprotective effects of liposome-encapsulated phenylaminoethyl selenide in human prostate cancer rodent models.

Authors:  Jeong Yeon Kang; Mathew Eggert; Shravanthi Mouli; Ibrahim Aljuffali; Xiaoyu Fu; Ben Nie; Amy Sheil; Kendall Waddey; Charlie D Oldham; Sheldon W May; Rajesh Amin; Robert D Arnold
Journal:  Pharm Res       Date:  2014-08-27       Impact factor: 4.200

3.  Extraction protocol and mass spectrometry method for quantification of doxorubicin released locally from prodrugs in tumor tissue.

Authors:  Stuart Ibsen; Yongxuan Su; John Norton; Eran Zahavy; Tomoko Hayashi; Stephen Adams; Wolf Wrasidlo; Sadik Esener
Journal:  J Mass Spectrom       Date:  2013-07       Impact factor: 1.982

4.  Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model.

Authors:  Robert D Arnold; Donald E Mager; Jeanine E Slack; Robert M Straubinger
Journal:  Clin Cancer Res       Date:  2005-12-15       Impact factor: 12.531

5.  Combination of micellar electrokinetic and high-performance liquid chromatographies to assess age-related changes in the in vitro metabolism of Fischer 344 rat liver.

Authors:  Yaohua Wang; Joseph B Katzenmeyer; Edgar A Arriaga
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-07-11       Impact factor: 6.053

6.  Bispecific antibody complex pre-targeted delivery of polymer-drug conjugates for cancer therapy.

Authors:  Keyur S Gada; Vishwesh Patil; Rajiv Panwar; Arash Hatefi; Ban-An Khaw
Journal:  Drug Deliv Transl Res       Date:  2012-02       Impact factor: 4.617

7.  Brainstem blood brain barrier disruption using focused ultrasound: A demonstration of feasibility and enhanced doxorubicin delivery.

Authors:  Saira Alli; Carlyn A Figueiredo; Brian Golbourn; Nesrin Sabha; Megan Yijun Wu; Andrew Bondoc; Amanda Luck; Daniel Coluccia; Colin Maslink; Christian Smith; Heiko Wurdak; Kullervo Hynynen; Meaghan O'Reilly; James T Rutka
Journal:  J Control Release       Date:  2018-05-16       Impact factor: 9.776

8.  CD19-Targeted Nanodelivery of Doxorubicin Enhances Therapeutic Efficacy in B-Cell Acute Lymphoblastic Leukemia.

Authors:  Vinu Krishnan; Xian Xu; Dakota Kelly; Adam Snook; Scott A Waldman; Robert W Mason; Xinqiao Jia; Ayyappan K Rajasekaran
Journal:  Mol Pharm       Date:  2015-05-04       Impact factor: 4.939

9.  Imaging doxorubicin and polymer-drug conjugates of doxorubicin-induced cardiotoxicity with bispecific anti-myosin-anti-DTPA antibody and Tc-99m-labeled polymers.

Authors:  Rajiv Panwar; Prashant Bhattarai; Vishwesh Patil; Keyur Gada; Stan Majewski; Ban An Khaw
Journal:  J Nucl Cardiol       Date:  2018-02-01       Impact factor: 5.952

10.  Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer.

Authors:  Tong Li; Yak-Nam Wang; Tatiana D Khokhlova; Samantha D'Andrea; Frank Starr; Hong Chen; Jeannine S McCune; Linda J Risler; Afshin Mashadi-Hossein; Sunil R Hingorani; Amy Chang; Joo Ha Hwang
Journal:  Cancer Res       Date:  2015-07-27       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.